2.

氨柔比星治疗敏感复发或难治性SCLC Ⅱ期临床研究结果

Phase Ⅱ study of amrubicin in relapsed case or refractory case with small lung cancer: response

	Sensitive cases (n)	Refractory cases (n)	Total (n)
∞:a symbol of infinite. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
No. of patients	44	16	60
CR	1	1	2
PR	22	7	29
SD	10	2	12
PD	11	6	17
Response rate (95%CI)	52% (37%-68%)	50% (25%-75%)	52% (38%-65%)
Progression-free survival (95%CI)/month	4.2 (3.6-5.3)	2.9 (1.4-4.6)	3.9 (3.4-4.6)
Median survival time (95%CI)/month	11.6 (10.0-15.8)	10.3 (4.8-∞)	11 (10.0-13.2)
1-year survival (95%CI)	45.5% (29.9-59.8)	40.3% (15.1-64.6)	44.1% (30.6-56.8)